Patents by Inventor Antje Margret Wengner
Antje Margret Wengner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9999623Abstract: Described herein arc methods of treating non-Hodgkin's lymphoma (NHL), wherein the non-Hodgkin's lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.Type: GrantFiled: April 4, 2014Date of Patent: June 19, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ningshu Liu, Katja Haike, Juliane Paul, Antje Margret Wengner
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20170342064Abstract: The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.Type: ApplicationFiled: December 7, 2015Publication date: November 30, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Volker SCHULZE, Hans-Georg LERCHEN, Ulrich LÜCKING, Antje Margret WENGNER, Gerhard SIEMEISTER, Philip LIENAU, Ursula KRENZ
-
Publication number: 20170260198Abstract: Compounds of formula (1) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: February 21, 2017Publication date: September 14, 2017Applicants: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
-
Publication number: 20170216304Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9682995Abstract: The present invention relates to isothiazoles of general formula (I) which inhibit the mitotic checkpoint: in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 28, 2014Date of Patent: June 20, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Bärfacker, Stefan Prechtl, Gerhard Siemeister, Antje Margret Wengner, Jens Ackerstaff, Katrin Nowak-Reppel, Benjamin Bader, Philip Lienau, Detlef Stöckigt, Tobias Heinrich
-
Patent number: 9676766Abstract: The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: November 17, 2010Date of Patent: June 13, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Volker Schulze, Marcus Koppitz, Dirk Kosemund, Hartmut Schirok, Benjamin Bader, Philip Lienau, Antje Margret Wengner, Hans Briem, Simon Holton, Gerhard Siemeister, Stefan Prechtl, Ulf Bömer
-
Patent number: 9670202Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: June 3, 2014Date of Patent: June 6, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hartmut Schirok, Volker Schulze, Dirk Kosemund, Hans Briem, Benjamin Bader, Ulf Bömer, Antje Margret Wengner, Gerhard Siemeister, Philip Lienau
-
Patent number: 9663510Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: December 10, 2012Date of Patent: May 30, 2017Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBHInventors: Volker Schulze, Dirk Kosemund, Antje Margret Wengner, Gerhard Siemeister, Detlef Stöckigt, Michael Brüning
-
Patent number: 9586958Abstract: The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.Type: GrantFiled: June 6, 2014Date of Patent: March 7, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Volker Schulze, Hans-Georg Lerchen, Donald Bierer, Antje Margret Wengner, Gerhard Siemeister, Philip Lienau, Ursula Krenz, Dirk Kosemund, Detlef Stöckigt, Michael Brüning, Ulrich Lücking, Ildikó Terebesi
-
Publication number: 20170029441Abstract: The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 6, 2015Publication date: February 2, 2017Inventors: Volker SCHULZE, Knut EIS, Florian PUEHLER, Ludwig ZORN, Detlev SÜLZLE, Philip LIENAU, Antje Margret WENGNER, Kirstin PETERSEN, Ulf BÖMER
-
Patent number: 9555022Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds.Type: GrantFiled: June 14, 2011Date of Patent: January 31, 2017Assignee: Bayer Intellectual Property GmbHInventors: Volker Schulze, Dirk Kosemund, Hartmut Schirok, Benjamin Bader, Philip Lienau, Antje Margret Wengner, Hans Briem, Simon Holton, Gerhard Siemeister, Stefan Prechtl, Marcus Koppitz, Detlef Stöckigt, Olaf Prien
-
Patent number: 9549932Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 19, 2016Date of Patent: January 24, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Franz Von Nussbaum, Benjamin Bader, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Dieter Moosmayer, Uwe Eberspächer, Hans Schick, Knut Eis, Marcus Koppitz, Antje Margret Wengner, Joanna Grudzinska-Goebel
-
Patent number: 9540392Abstract: The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 17, 2013Date of Patent: January 10, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Georg Kettschau, Florian Puehler, Knut Eis, Ulrich Klar, Dirk Kosemund, Detlev Sülzle, Philip Lienau, Andrea Hägebarth, Ulf Bömer, Lars Wortmann, Keith Graham, Antje Margret Wengner
-
Patent number: 9512130Abstract: The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: February 25, 2014Date of Patent: December 6, 2016Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Ulrich Klar, Antje Margret Wengner, Roland Neuhaus, Gerhard Siemeister, Michael Brüning
-
Patent number: 9512126Abstract: The present invention relates to substituted imidazopyridazine compounds of general formula I in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: March 11, 2013Date of Patent: December 6, 2016Assignee: Bayer Intellectual Property GmbHInventors: Marcus Koppitz, Ulrich Klar, Antje Margret Wengner, Roland Neuhaus, Gerhard Siemeister
-
Publication number: 20160297811Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: June 3, 2014Publication date: October 13, 2016Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hartmut SCHIROK, Volker SCHULZE, Dirk KOSEMUND, Hans BRIEM, Benjamin BADER, Ulf BÖMER, Antje Margret WENGNER, Gerhard SIEMEISTER, Philip LIENAU
-
Publication number: 20160287589Abstract: The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): (Ia) (Ib) (Ic) (Id) in which A, Y, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: February 18, 2014Publication date: October 6, 2016Inventors: Knut FIS, Florian PUEHLER, Ludwig ZORN, Volker SCHULZE, Detlev SÜLZLE, Philip LIENAU, Antje Margret WENGNER, Kirstin PETERSEN, Ulf BÖMER
-
Publication number: 20160287604Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 19, 2016Publication date: October 6, 2016Inventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Franz Von Nussbaum, Benjamin Bader, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Dieter Moosmayer, Uwe Eberspächer, Hans Schick, Knut Eis, Marcus Koppitz, Antje Margret Wengner, Joanna Grudzinska-Goebel
-
Publication number: 20160264568Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: June 3, 2014Publication date: September 15, 2016Inventors: Volker K. SCHULZE, Andreas SCHALL, Hans BRIEM, Antje Margret WENGNER, Gerhard SIEMEISTER, Detlef STÖCKIGT, Philip LIENAU